Proof of Concept Study on LTX-109 as Treatment for Hidradenitis Suppurativa
Latest Information Update: 30 Mar 2023
At a glance
- Drugs LTX 109 (Primary)
- Indications Hidradenitis suppurativa
- Focus Adverse reactions; Proof of concept
- Sponsors Pharma Holdings AS
- 27 Aug 2021 Status changed from recruiting to completed.
- 04 Mar 2021 Status changed from not yet recruiting to recruiting.
- 17 Feb 2021 New trial record